U.S. Markets close in 6 hrs 13 mins
  • S&P 500

    +9.44 (+0.24%)
  • Dow 30

    +226.06 (+0.71%)
  • Nasdaq

    -51.20 (-0.44%)
  • Russell 2000

    +12.81 (+0.74%)
  • Crude Oil

    -0.33 (-0.49%)
  • Gold

    +14.80 (+0.75%)
  • Silver

    +0.09 (+0.39%)

    +0.0062 (+0.5796%)
  • 10-Yr Bond

    +0.0340 (+1.00%)
  • Vix

    +0.52 (+2.04%)

    +0.0083 (+0.6790%)

    -0.2710 (-0.2056%)

    +673.29 (+2.47%)
  • CMC Crypto 200

    +7.48 (+1.25%)
  • FTSE 100

    +31.32 (+0.43%)
  • Nikkei 225

    -388.12 (-1.42%)

TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day. This change was narrower than the S&P 500's daily loss of 1.3%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 5.51%.

Heading into today, shares of the biopharmaceutical company had gained 23.67% over the past month, outpacing the Medical sector's loss of 0.54% and the S&P 500's gain of 6.41% in that time.

Wall Street will be looking for positivity from TG Therapeutics as it approaches its next earnings report date. On that day, TG Therapeutics is projected to report earnings of -$0.26 per share, which would represent year-over-year growth of 62.86%. Meanwhile, our latest consensus estimate is calling for revenue of $0.04 million, down 98.28% from the prior-year quarter.

It is also important to note the recent changes to analyst estimates for TG Therapeutics. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.82% higher. TG Therapeutics is currently sporting a Zacks Rank of #2 (Buy).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 145, putting it in the bottom 43% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research